Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Stephens Analyst Says

Immunome (NASDAQ:IMNM) had its price objective boosted by equities research analysts at Stephens from $25.00 to $33.00 in a research report issued on Monday, MarketBeat.com reports. The brokerage currently has an “overweight” rating on the stock. Stephens’ target price would suggest a potential upside of 84.77% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group initiated coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price on the stock. Evercore ISI assumed coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price target on the stock. Guggenheim restated a “buy” rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase & Co. lowered their target price on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, Wedbush reiterated an “outperform” rating and set a $21.00 price target on shares of Immunome in a research note on Friday, November 7th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.78.

Immunome Stock Down 1.5%

NASDAQ IMNM opened at $17.86 on Monday. The stock has a market capitalization of $1.64 billion, a PE ratio of -6.05 and a beta of 1.96. The firm has a 50 day moving average of $13.89 and a two-hundred day moving average of $10.94. Immunome has a 52 week low of $5.15 and a 52 week high of $18.79.

Immunome (NASDAQ:IMNM) last posted its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, equities research analysts expect that Immunome will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock worth $50,843,000 after buying an additional 2,054,640 shares during the period. Redmile Group LLC raised its stake in Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock valued at $36,081,000 after acquiring an additional 533,161 shares during the last quarter. Vanguard Group Inc. lifted its position in Immunome by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock worth $57,304,000 after acquiring an additional 368,674 shares during the period. EcoR1 Capital LLC grew its stake in shares of Immunome by 5.2% in the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock valued at $27,454,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Primecap Management Co. CA grew its stake in shares of Immunome by 1,115.7% in the 1st quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company’s stock valued at $22,974,000 after purchasing an additional 3,132,900 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.